1. Market Research
6 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Chile

  • $ 1870
  • June 2017
  • 44 pages

lymphoma in patients aged ## and over, HIV/ AIDS, and primary hypertension in patients aged ## and over.

  • Health Services
  • Healthcare
  • Hospital
  • Lymphoma
  • Chile

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Brazil

  • $ 1700
  • March 2017
  • 44 pages

Rituximab for follicular lymphoma and diffuse large B-cell lymphoma.

  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Pharmacy
  • Brazil

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: UK

  • $ 1700
  • December 2016
  • 67 pages

U ITE KINGDOM CANADA IMS Pharmaceutical Pricing & Reimbursement Concise Guide Published December 2014 Published September 2014 The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions.

  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United Kingdom

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Sweden

  • $ 1700
  • December 2016
  • 43 pages

SWE EN CANADA IMS Pharmaceutical Pricing & Reimbursement Concise Guide Published December 2014 Published September 2014 The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions.

  • Hospital
  • Lymphoma
  • Pharmaceutical
  • Pharmacy
  • Sweden

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Germany

  • $ 1700
  • June 2016
  • 50 pages

In this respect, the G-BA in March 2016 resolved that the monoclonal antibody rituximab qualifies for statutory reimbursement as an off-label treatment for mantle cell lymphoma (MCL).

  • Health Insurance
  • Pharmaceutical
  • Therapy
  • Germany
  • AbbVie Inc.

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: France

  • $ 1700
  • December 2016
  • 83 pages

ASMR III: eight awarded, including to Xalkori (crizotinib) for patients with metastatic nonsmall cell lung cancer whose tumours are anaplastic lymphoma kinase-positive and who have received at least one other treatment, and Perjeta (pertuzumab) indicated for the treatment of patients with H

  • Hospital
  • Lymphoma
  • Pharmaceutical
  • France


View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on